Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)

11/18/2020 | 05:18pm EST
Item 8.01 Other Events.



On November 18, 2020, AbbVie Inc. issued a press release announcing the expiration and final results of its offers to exchange any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019, (ii) $13,251,781,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 and (iii) €2,517,066,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020, each issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), for an equal principal amount of new notes in a transaction registered under the Securities Act. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein in its entirety.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
  No.      Exhibit

  99.1       Press Release dated November 18, 2020.
104        The cover page from this Current Report on Form 8-K formatted in Inline
           XBRL (included as Exhibit 101).




                                       2

© Edgar Online, source Glimpses

All news about ABBVIE INC.
01/18ABBVIE : Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neur..
AQ
01/15ABBVIE : Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neur..
PR
01/14ABBVIE INC. : Ex-dividend day for
FA
01/13SECTOR UPDATE : Health Care Stocks Rise in Cautious Wednesday Trade
MT
01/13SECTOR UPDATE : Health Care Stocks Maintaining Moderate Advance
MT
01/13GENMAB A/S : to Receive $40 Million Milestone Payment From AbbVie
MT
01/13HARPOON THERAPEUTICS : FDA Grants Orphan Drug Status to Harpoon Therapeutics, Ab..
MT
01/12ABBVIE : J.P. Morgan Healthcare Conference Presentation 985.1 KB
PU
01/12ABBVIE INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
01/12ABBVIE : Unit Allergan Enters Into Option to Buy Cypris Medical
MT
More news
Financials (USD)
Sales 2020 45 626 M - -
Net income 2020 12 344 M - -
Net Debt 2020 75 457 M - -
P/E ratio 2020 27,2x
Yield 2020 4,30%
Capitalization 196 B 196 B -
EV / Sales 2020 5,94x
EV / Sales 2021 4,80x
Nbr of Employees 47 000
Free-Float 98,5%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 115,91 $
Last Close Price 110,86 $
Spread / Highest target 21,8%
Spread / Average Target 4,55%
Spread / Lowest Target -12,5%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.3.46%195 720
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159